Unknown Status PHASE2 Interventional 2-arm NCT01281423

Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype-1 Patients With Chronic HCV Infection

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of ANA598 Administered With Pegylated Interferon and Ribavirin in Genotype 1 Patients With Chronic Hepatitis C Infection

Sponsor: Hoffmann-La Roche

Conditions Hepatitis C

Interventions ANA598 Pegylated Interferon Placebo Ribavirin

Updated 2 times since 2017 Last updated: Jan 20, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Hepatitis C and is currently ongoing. Hoffmann-La Roche leads this study, which shows 2 recorded versions since 2026 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

2 versions recorded

Feb 2017 — Present [monthly]

Unknown Status PHASE2
Jan 2017 — Feb 2017 [monthly]

Unknown Status PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Hoffmann-La Roche

Data source: Hoffmann-La Roche

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arlington, United States , Asheville, United States , Bakersfield, United States , Bellevue, United States , Bradenton, United States , Chapel Hill, United States , Chicago, United States , Christchurch, New Zealand , Cincinnati, United States , Clayton, Australia and 32 more locations